Viking Therapeutics, Inc. (VKTX) Financial Statements
Viking Therapeutics, Inc. (VKTX) reported trailing twelve-month revenue of $0 (up 0.0% year on year) and net income of -$534.8M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$418.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VKTXViking Therapeutics, Inc.Follow VKTX — free
—
Price chart with a free account
- Market cap
- 2.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Research & development | 7.0 | 9.0 | 13.7 | 19.0 | 23.6 | 31.9 | 45.0 | 54.2 | 63.8 | 101.6 | 345.0 | 509.3 | |
| Operating income | -12.0 | -13.8 | -19.1 | -26.2 | -32.7 | -42.7 | -55.7 | -70.4 | -100.8 | -150.9 | -393.3 | -560.0 | |
| Pre-tax income | -23.4 | -14.7 | -20.6 | -22.1 | -25.8 | -39.5 | -55.0 | -68.9 | -85.9 | -110.0 | -359.6 | -534.8 | |
| Income tax | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -23.4 | -14.7 | -20.6 | -22.1 | -25.8 | -39.5 | -55.0 | -68.9 | -85.9 | -110.0 | -359.6 | -534.8 | |
| Diluted EPS ($) | -3.68 | -0.90 | -0.79 | -0.38 | -0.36 | -0.54 | -0.71 | -0.90 | -0.91 | -1.01 | -3.19 | -4.67 | |
| Diluted shares (mn) | — | — | — | — | — | — | — | 76.8 | 94.3 | 109.0 | 112.7 | — |
USD millions · SEC XBRL
Viking Therapeutics, Inc. — questions
- What is Viking Therapeutics, Inc.'s revenue?
- $0 over the twelve months to 2026-06-30, up 0.0% year on year, from its 10-Q and 10-K filings.
- What is Viking Therapeutics, Inc.'s net income?
- -$534.8M over the twelve months to 2026-06-30.
- What is Viking Therapeutics, Inc.'s free cash flow?
- -$418.4M over the twelve months to 2026-06-30.
- What are Viking Therapeutics, Inc.'s diluted earnings per share?
- $-4.67 over the twelve months to 2026-06-30.
Every figure on this page comes from Viking Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.